Abbratech Inc

AbbraTech Inc., founded in 2020 in Branford, Connecticut, is at the forefront of antibody discovery and engineering, targeting human diseases such as cancer, immune disorders, and viral infections. The company leverages its innovative EPIVOLVE technology, which facilitates site-specific antibody discovery, overcoming challenges like low immunogenicity and immune tolerance.

With a team of experienced scientists skilled in antibody engineering and a commitment to tackling difficult antigen targets, AbbraTech aims to develop next-generation medicines in collaboration with industry and academic partners. Their mission is to empower discovery efforts against drug targets that traditional methods cannot reach.

Generated from the website